Hot Life Science Investor Mandate 2: European VC Seeking Orphan Therapeutics in North America and Europe

7 Aug

A European VC firm has recently closed €75 million and is looking to make its first allocations. The firm is looking to invest in Europe and North America, and typically allocates about €5 million equity to each portfolio company, generally over several tranches. The firm has no set number of allocations that it plans to make over the next 6-9 months but they are actively seeking new opportunities.

The firm invests in therapeutics to treat rare diseases. The firm is agnostic regarding technology type and indication areas pending the targeted market can have expedited regulatory approval through a rare/orphan status. The fund typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: